

Pembrolizumab+FP

2022.2作成


・Pembrolizumab

・Day1





・5-FU (Pembrolizumab終了後開始)

・Day1-4





・CDDP (Pembrolizumab終了後開始)

・Day 1



・Day 2、3



3週毎に施行

Head and Neck Cancer